Placental extract formulation Regenerin (Patent no- RU 2469704 CI, dt: 07.07.2011) has been reported to possess antioxidant, antimicrobial, anti-inflammatory, cellular proliferation, and tissue regeneration properties. Considering the properties of placental extract, the present investigation was undertaken to investigate the effectiveness of this formulation in rat diabetic foot ulcer (DFU). Diabetes was induced by intraperitoneal (i.p) injection of 65 mg/kg of Streptozotocin (STZ) in rats and open excision wounds were produced in feet by using scalpel. The formulations were topically applied to all the groups once a day till the complete healing was achieved. Blood glucose monitoring, body weight, food and water content, parameters were measured weekly. Wound healing was assessed by analyzing % wound closure,wound area measurements, hydroxyproline content, epithelialization period, and inflammatory marker CRP At the end of study, foot was excised for histopathology and hydroxyproline level. Treatment with Regenerin gel produced decrease in wound size and increased epithelization from 8th day which continued until 18 days when complete closure was found. Regenerin-gel showed the higher hydroxyproline content, decrease in inflammatory markers, neovascularization as well as increases the collagen deposition. It can be concluded from this study that topically applied regernerin-gel may be a potential approach for faster wound healing for treatment of chronic diabetic wounds.